Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.

Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE.

Expert Opin Investig Drugs. 2011 Dec;20(12):1677-84. doi: 10.1517/13543784.2011.631523. Epub 2011 Oct 28. Review.

2.

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

Dai Y, Siemann DW.

Mol Cancer Ther. 2010 Jun;9(6):1554-61. doi: 10.1158/1535-7163.MCT-10-0359. Epub 2010 Jun 1.

3.

Targeting the HGF/Met signaling pathway in cancer therapy.

Cecchi F, Rabe DC, Bottaro DP.

Expert Opin Ther Targets. 2012 Jun;16(6):553-72. doi: 10.1517/14728222.2012.680957. Epub 2012 Apr 25. Review.

4.

A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.

Yu Y, Chen Y, Ding G, Wang M, Wu H, Xu L, Rui X, Zhang Z.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):154-60. doi: 10.1016/j.bbrc.2015.06.107. Epub 2015 Jun 18.

PMID:
26093299
5.

Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.

Nakashiro K, Hara S, Shinohara Y, Oyasu M, Kawamata H, Shintani S, Hamakawa H, Oyasu R.

Am J Pathol. 2004 Aug;165(2):533-40.

6.
7.

c-met proto-oncogene expression in benign and malignant human prostate tissues.

Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW.

J Urol. 1995 Jul;154(1):293-8.

PMID:
7539865
8.

The scatter factor signaling pathways as therapeutic associated target in cancer treatment.

Accornero P, Pavone LM, Baratta M.

Curr Med Chem. 2010;17(25):2699-712. Review.

PMID:
20586722
9.

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML.

Am J Pathol. 1995 Aug;147(2):386-96.

10.

Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.

Ghatak S, Hascall VC, Markwald RR, Misra S.

J Biol Chem. 2010 Jun 25;285(26):19821-32. doi: 10.1074/jbc.M110.104273. Epub 2010 Mar 3.

11.
12.

Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor.

Nishimura K, Kitamura M, Takada S, Nonomura N, Tsujimura A, Matsumiya K, Miki T, Matsumoto K, Okuyama A.

Int J Urol. 1998 May;5(3):276-81.

13.

MET and VEGF: synergistic targets in castration-resistant prostate cancer.

Aftab DT, McDonald DM.

Clin Transl Oncol. 2011 Oct;13(10):703-9. doi: 10.1007/s12094-011-0719-5. Review.

14.

Prostate cancer and the met hepatocyte growth factor receptor.

Knudsen BS, Edlund M.

Adv Cancer Res. 2004;91:31-67. Review.

PMID:
15327888
15.

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS.

Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158/2159-8290.CD-13-1010. Epub 2014 Aug 13.

16.

HGF/MET signaling in ovarian cancer.

Zhou HY, Pon YL, Wong AS.

Curr Mol Med. 2008 Sep;8(6):469-80. Review.

PMID:
18781954
17.

Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.

Matsumoto K, Nakamura T, Sakai K, Nakamura T.

Proteomics. 2008 Aug;8(16):3360-70. doi: 10.1002/pmic.200800156. Review.

PMID:
18646008
18.

Activation of c-MET induces a stem-like phenotype in human prostate cancer.

van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W, Jenster G.

PLoS One. 2011;6(11):e26753. doi: 10.1371/journal.pone.0026753. Epub 2011 Nov 14.

19.

Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.

Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O, Yano S.

Cancer Sci. 2013 Dec;104(12):1640-6. doi: 10.1111/cas.12301. Epub 2013 Nov 13.

20.

Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE.

Int J Cancer. 2013 Oct 1;133(7):1536-46. doi: 10.1002/ijc.28169. Epub 2013 Apr 17.

Supplemental Content

Support Center